By repositioning an HIV drug to target MITF as a driver of MAPK inhibitor (MAPKi)-induced drug tolerance we identify a clinically relevant approach for melanoma therapy that has the potential to improve initial responses and delay the onset of resistance. The gene discussed is MITF; the disease is melanoma.